HCA Healthcare, Inc 10-Q for FY2020 Q3
HCA Healthcare, Inc. (HCA)
About this 10-Q
HCA Healthcare, Inc filed this 10-Q on October 29, 2020, covering the quarter ended September 30, 2020 (FY2020 Q3).
Headline figures
Quarter ended September 30, 2020, as reported in this filing, compared with the same period a year earlier where the filing states it.
- Revenue
- $13.31B
- up 4.9% from $12.69B a year earlier
- Net income
- $668M
- up 9.2% from net income of $612M a year earlier
- Diluted EPS
- $1.95
- up 10.8% from $1.76 a year earlier
| QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
| TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
| (State or other jurisdiction of incorporation or organization) |
(I.R.S. Employer Identification No.) | |
| |
||
| (Address of principal executive offices) |
(Zip Code) | |
| Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered | ||
| |
|
|
|
|
Voting |
| |
☒ |
Accelerated filer |
☐ | |||
| Non-accelerated filer |
☐ |
Smaller reporting company |
||||
Emerging growth company |
| Class of Common Stock |
Outstanding at October 26, 2020 | |
| |
|
|
Voting common stock, $.01 par value |
Page of Form 10-Q |
||||||
| Part I. |
Financial Information |
|||||
| |
|
|
|
|
|
|
| Item 1. |
Financial Statements (Unaudited): |
|||||
2 |
||||||
3 |
||||||
4 |
||||||
5 |
||||||
6 |
||||||
7 |
||||||
| Item 2. |
20 |
|||||
| Item 3. |
40 |
|||||
| Item 4. |
40 |
|||||
| Part II. |
Other Information |
|||||
| Item 1. |
40 |
|||||
| Item 1A. |
41 |
|||||
| Item 2. |
44 |
|||||
| Item 6. |
45 |
|||||
46 |
||||||
Quarter |
Nine Months |
|||||||||||||||
2020 |
2019 |
2020 |
2019 |
|||||||||||||
| Revenues |
$ |
$ |
$ |
$ |
||||||||||||
| Salaries and benefits |
||||||||||||||||
| Supplies |
||||||||||||||||
| Other operating expenses |
||||||||||||||||
| Government stimulus income reversal |
— |
— |
||||||||||||||
| Equity in earnings of affiliates |
( |
) |
( |
) |
( |
) |
( |
) | ||||||||
| Depreciation and amortization |
||||||||||||||||
| Interest expense |
||||||||||||||||
| Losses (gains) on sales of facilities |
( |
) |
( |
) | ||||||||||||
| Losses on retirement of debt |
||||||||||||||||
| |
|
|
|
|
|
|
|
|||||||||
| |
|
|
|
|
|
|
|
|||||||||
| Income before income taxes |
||||||||||||||||
| Provision for income taxes |
||||||||||||||||
| |
|
|
|
|
|
|
|
|||||||||
| Net income |
||||||||||||||||
| Net income attributable to noncontrolling interests |
||||||||||||||||
| |
|
|
|
|
|
|
|
|||||||||
| Net income attributable to HCA Healthcare, Inc. |
$ |
$ |
$ |
$ |
||||||||||||
| |
|
|
|
|
|
|
|
|||||||||
| Per share data: |
||||||||||||||||
| Basic earnings |
$ |
$ |
$ |
$ |
||||||||||||
| Diluted earnings |
$ |
$ |
$ |
$ |
||||||||||||
| Shares used in earnings per share calculations (in millions): |
||||||||||||||||
| Basic |
||||||||||||||||
| Diluted |
||||||||||||||||
Quarter |
Nine Months |
|||||||||||||||
2020 |
2019 |
2020 |
2019 |
|||||||||||||
| Net income |
$ |
$ |
$ |
$ |
||||||||||||
| Other comprehensive income (loss) before taxes: |
||||||||||||||||
| Foreign currency translation |
( |
) |
( |
) |
( |
) | ||||||||||
| Unrealized gains on available-for-sale |
||||||||||||||||
| Defined benefit plans |
||||||||||||||||
| Pension costs included in salaries and benefits |
||||||||||||||||
| |
|
|
|
|
|
|
|
|||||||||
| Change in fair value of derivative financial instruments |
( |
) |
( |
) |
( |
) | ||||||||||
| Interest expense (benefits) included in interest expense |
( |
) |
( |
) | ||||||||||||
| |
|
|
|
|
|
|
|
|||||||||
( |
) |
( |
) |
( |
) | |||||||||||
| |
|
|
|
|
|
|
|
|||||||||
| Other comprehensive income (loss) before taxes |
( |
) |
( |
) |
( |
) | ||||||||||
| Income taxes (benefits) related to other comprehensive income items |
( |
) |
( |
) |
( |
) | ||||||||||
| |
|
|
|
|
|
|
|
|||||||||
| Other comprehensive income (loss) |
( |
) |
( |
) |
( |
) | ||||||||||
| |
|
|
|
|
|
|
|
|||||||||
| Comprehensive income |
||||||||||||||||
| Comprehensive income attributable to noncontrolling interests |
||||||||||||||||
| |
|
|
|
|
|
|
|
|||||||||
| Comprehensive income attributable to HCA Healthcare, Inc. |
$ |
$ |
$ |
$ |
||||||||||||
| |
|
|
|
|
|
|
|
|||||||||
September 30, 2020 |
December 31, 2019 |
|||||||
ASSETS |
||||||||
| Current assets: |
||||||||
| Cash and cash equivalents |
$ |
$ |
||||||
| Accounts receivable |
||||||||
| Inventories |
||||||||
| Other |
||||||||
| |
|
|
|
|||||
| |
|
|
|
|
|
|
|
|
| Property and equipment, at cost |
||||||||
| Accumulated depreciation |
( |
) |
( |
) | ||||
| |
|
|
|
|||||
| |
|
|
|
|
|
|
| |
| Investments of insurance subsidiaries |
||||||||
| Investments in and advances to affiliates |
||||||||
| Goodwill and other intangible assets |
||||||||
| Right-of-use |
||||||||
| Other |
||||||||
| |
|
|
|
|||||
$ |
$ |
|||||||
| |
|
|
|
|||||
LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) |
||||||||
| Current liabilities: |
||||||||
| Accounts payable |
$ |
$ |
||||||
| Accrued salaries |
||||||||
| Other accrued expenses |
||||||||
| Government stimulus refund liability |
— |
|||||||
| Long-term debt due within one year |
||||||||
| |
|
|
|
|||||
| Long-term debt, less debt issuance costs and discounts of $ |
||||||||
| Professional liability risks |
||||||||
| Right-of-use |
||||||||
| Income taxes and other liabilities |
||||||||
| Stockholders’ equity (deficit): |
||||||||
| Common stock $ |
||||||||
| Capital in excess of par value |
— |
|||||||
| Accumulated other comprehensive loss |
( |
) |
( |
) | ||||
| Retained deficit |
( |
) |
( |
) | ||||
| |
|
|
|
|||||
| Stockholders’ deficit attributable to HCA Healthcare, Inc. |
( |
) |
( |
) | ||||
| Noncontrolling interests |
||||||||
| |
|
|
|
|||||
( |
) | |||||||
| |
|
|
|
|||||
$ |
$ |
|||||||
| |
|
|
|
|||||
Equity (Deficit) Attributable to HCA Healthcare, Inc. |
Equity Attributable to Noncontrolling Interests |
Total |
||||||||||||||||||||||||||
Common Stock |
Capital in Excess of Par Value |
Accumulated Other Comprehensive Loss |
Retained Deficit |
|||||||||||||||||||||||||
Shares (in millions) |
Par Value |
|||||||||||||||||||||||||||
| Balances, December 31, 2018 |
$ |
$ |
— |
$ |
( |
) |
$ |
( |
) |
$ |
$ |
( |
) | |||||||||||||||
| Comprehensive income |
||||||||||||||||||||||||||||
| Repurchase of common stock |
( |
) |
( |
) |
( |
) | ||||||||||||||||||||||
| Share-based benefit plans |
( |
) |
( |
) | ||||||||||||||||||||||||
| Cash dividends declared ($ |
( |
) |
( |
) | ||||||||||||||||||||||||
| Distributions |
( |
) |
( |
) | ||||||||||||||||||||||||
| Other |
( |
) |
||||||||||||||||||||||||||
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
| Balances, March 31, 2019 |
— |
( |
) |
( |
) |
( |
) | |||||||||||||||||||||
| Comprehensive income |
( |
) |
||||||||||||||||||||||||||
| Repurchase of common stock |
( |
) |
( |
) |
( |
) |
( |
) | ||||||||||||||||||||
| Share-based benefit plans |
||||||||||||||||||||||||||||
| Cash dividends declared ($ |
( |
) |
( |
) | ||||||||||||||||||||||||
| Distributions |
( |
) |
( |
) | ||||||||||||||||||||||||
| Other |
( |
) |
( |
) | ||||||||||||||||||||||||
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
| Balances, June 30, 2019 |
— |
( |
) |
( |
) |
( |
) | |||||||||||||||||||||
| Comprehensive income |
( |
) |
||||||||||||||||||||||||||
| Repurchase of common stock |
( |
) |
( |
) |
( |
) |
( |
) | ||||||||||||||||||||
| Share-based benefit plans |
||||||||||||||||||||||||||||
| Cash dividends declared ($ |
( |
) |
( |
) | ||||||||||||||||||||||||
| Distributions |
( |
) |
( |
) | ||||||||||||||||||||||||
| Other |
( |
) |
( |
) | ||||||||||||||||||||||||
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
| Balances, September 30, 2019 |
— |
( |
) |
( |
) |
( |
) | |||||||||||||||||||||
| Comprehensive income |
||||||||||||||||||||||||||||
| Repurchase of common stock |
( |
) |
( |
) |
( |
) |
( |
) | ||||||||||||||||||||
| Share-based benefit plans |
||||||||||||||||||||||||||||
| Cash dividends declared ($ |
( |
) |
( |
) | ||||||||||||||||||||||||
| Distributions |
( |
) |
( |
) | ||||||||||||||||||||||||
| Other |
( |
) |
||||||||||||||||||||||||||
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
| Balances, December 31, 2019 |
— |
( |
) |
( |
) |
( |
) | |||||||||||||||||||||
| Comprehensive income |
( |
) |
||||||||||||||||||||||||||
| Repurchase of common stock |
( |
) |
( |
) |
( |
) | ||||||||||||||||||||||
| Share-based benefit plans |
( |
) |
( |
) | ||||||||||||||||||||||||
| Cash dividends declared ($ |
( |
) |
( |
) | ||||||||||||||||||||||||
| Distributions |
( |
) |
( |
) | ||||||||||||||||||||||||
| Other |
( |
) |
||||||||||||||||||||||||||
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
| Balances, March 31, 2020 |
— |
( |
) |
( |
) |
( |
) | |||||||||||||||||||||
| Comprehensive income |
||||||||||||||||||||||||||||
| Share-based benefit plans |
||||||||||||||||||||||||||||
| Distributions |
( |
) |
( |
) | ||||||||||||||||||||||||
| Other |
( |
) |
( |
) | ||||||||||||||||||||||||
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
| Balances, June 30, 2020 |
( |
) |
( |
) |
||||||||||||||||||||||||
| Comprehensive income |
||||||||||||||||||||||||||||
| Share-based benefit plans |
||||||||||||||||||||||||||||
| Distributions |
( |
) |
( |
) | ||||||||||||||||||||||||
| Other |
||||||||||||||||||||||||||||
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
| Balances, September 30, 2020 |
$ |
$ |
$ |
( |
) |
$ |
( |
) |
$ |
$ |
||||||||||||||||||
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
2020 |
2019 |
|||||||
| Cash flows from operating activities: |
||||||||
| Net income |
$ |
$ |
||||||
| Adjustments to reconcile net income to net cash provided by operating activities: |
||||||||
| Increase (decrease) in cash from operating assets and liabilities: |
||||||||
| Accounts receivable |
( |
) | ||||||
| Inventories and other assets |
( |
) |
( |
) | ||||
| Accounts payable and accrued expenses |
( |
) | ||||||
| Government stimulus refund liability |
— |
|||||||
| Depreciation and amortization |
||||||||
| Income taxes |
( |
) |
||||||
| Losses (gains) on sales of facilities |
( |
) | ||||||
| Losses on retirement of debt |
||||||||
| Amortization of debt issuance costs and discounts |
||||||||
| Share-based compensation |
||||||||
| Other |
||||||||
| |
|
|
|
|||||
| Net cash provided by operating activities |
||||||||
| |
|
|
|
|||||
| Cash flows from investing activities: |
||||||||
| Purchase of property and equipment |
( |
) |
( |
) | ||||
| Acquisition of hospitals and health care entities |
( |
) |
( |
) | ||||
| Sales of hospitals and health care entities |
||||||||
| Change in investments |
( |
) |
||||||
| Other |
( |
) |
||||||
| |
|
|
|
|||||
| Net cash used in investing activities |
( |
) |
( |
) | ||||
| |
|
|
|
|||||
| Cash flows from financing activities: |
||||||||
| Issuances of long-term debt |
||||||||
| Net change in revolving bank credit facilities |
( |
) |
( |
) | ||||
| Repayment of long-term debt |
( |
) |
( |
) | ||||
| Distributions to noncontrolling interests |
( |
) |
( |
) | ||||
| Payment of debt issuance costs |
( |
) |
( |
) | ||||
| Payment of dividends |
( |
) |
( |
) | ||||
| Repurchases of common stock |
( |
) |
( |
) | ||||
| Other |
( |
) |
( |
) | ||||
| |
|
|
|
|||||
| Net cash used in financing activities |
( |
) |
( |
) | ||||
| |
|
|
|
|||||
| Effect of exchange rate changes on cash and cash equivalents |
( |
) |
( |
) | ||||
| |
|
|
|
|||||
| Change in cash and cash equivalents |
||||||||
| Cash and cash equivalents at beginning of period |
||||||||
| |
|
|
|
|||||
| Cash and cash equivalents at end of period |
$ |
$ |
||||||
| |
|
|
|
|||||
| Interest payments |
$ |
$ |
||||||
| Income tax payments, net |
$ |
$ |
||||||
Quarter |
||||||||||||||||
2020 |
Ratio |
2019 |
Ratio |
|||||||||||||
| Medicare |
$ |
% |
$ |
% | ||||||||||||
| Managed Medicare |
||||||||||||||||
| Medicaid |
||||||||||||||||
| Managed Medicaid |
||||||||||||||||
| Managed care and insurers |
||||||||||||||||
| International (managed care and insurers) |
||||||||||||||||
| Other |
||||||||||||||||
| |
|
|
|
|
|
|
|
|||||||||
| Revenues |
$ |
% |
$ |
% | ||||||||||||
| |
|
|
|
|
|
|
|
|||||||||
Nine Months |
||||||||||||||||
2020 |
Ratio |
2019 |
Ratio |
|||||||||||||
| Medicare |
$ |
% |
$ |
% | ||||||||||||
| Managed Medicare |
||||||||||||||||
| Medicaid |
||||||||||||||||
| Managed Medicaid |
||||||||||||||||
| Managed care and insurers |
||||||||||||||||
| International (managed care and insurers) |
||||||||||||||||
| Other |
||||||||||||||||
| |
|
|
|
|
|
|
|
|||||||||
| Revenues |
$ |
% |
$ |
% | ||||||||||||
| |
|
|
|
|
|
|
|
|||||||||
Quarter |
Nine Months |
|||||||||||||||
2020 |
2019 |
2020 |
2019 |
|||||||||||||
| Patient care costs (salaries and benefits, supplies, other operating expenses and depreciation and amortization) |
$ |
$ |
$ |
$ |
||||||||||||
| Cost-to-charges |
% |
% |
% |
% | ||||||||||||
| Total uncompensated care |
$ |
$ |
$ |
$ |
||||||||||||
| Multiply by the cost-to-charges |
% |
% |
% |
% | ||||||||||||
| |
|
|
|
|
|
|
|
|||||||||
| Estimated cost of total uncompensated care |
$ |
$ |
$ |
$ |
||||||||||||
| |
|
|
|
|
|
|
|
|||||||||
Quarter |
Nine Months |
|||||||||||||||
2020 |
2019 |
2020 |
2019 |
|||||||||||||
| Net income attributable to HCA Healthcare, Inc. |
$ |
$ |
$ |
$ |
||||||||||||
| Weighted average common shares outstanding |
||||||||||||||||
| Effect of dilutive incremental shares |
||||||||||||||||
| |
|
|
|
|
|
|
|
|||||||||
| Shares used for diluted earnings per share |
||||||||||||||||
| |
|
|
|
|
|
|
|
|||||||||
| Earnings per share: |
||||||||||||||||
| Basic earnings |
$ |
$ |
$ |
$ |
||||||||||||
| Diluted earnings |
$ |
$ |
$ |
$ |
||||||||||||
September 30, 2020 |
||||||||||||||||
Amortized Cost |
Unrealized Amounts |
Fair Value |
||||||||||||||
Gains |
Losses |
|||||||||||||||
| Debt securities |
$ |
$ |
$ |
— |
$ |
|||||||||||
| Money market funds and other |
— |
— |
||||||||||||||
| |
|
|
|
|
|
|
|
|||||||||
$ |
$ |
$ |
— |
|||||||||||||
| |
|
|
|
|
|
|||||||||||
| Amounts classified as current assets |
( |
) | ||||||||||||||
| |
|
|||||||||||||||
| Investment carrying value |
$ |
|||||||||||||||
| |
|
|||||||||||||||
December 31, 2019 |
||||||||||||||||
Amortized Cost |
Unrealized Amounts |
Fair Value |
||||||||||||||
Gains |
Losses |
|||||||||||||||
| Debt securities |
$ |
$ |
$ |
— |
$ |
|||||||||||
| Money market funds and other |
— |
— |
||||||||||||||
| |
|
|
|
|
|
|
|
|||||||||
$ |
$ |
$ |
— |
|||||||||||||
| |
|
|
|
|
|
|||||||||||
| Amounts classified as current assets |
( |
) | ||||||||||||||
| |
|
|||||||||||||||
| Investment carrying value |
$ |
|||||||||||||||
| |
|
|||||||||||||||
Amortized Cost |
Fair Value |
|||||||
| Due in one year or less |
$ |
$ |
||||||
| Due after one year through five years |
||||||||
| Due after five years through ten years |
||||||||
| Due after ten years |
||||||||
| |
|
|
|
|||||
$ |
$ |
|||||||
| |
|
|
|
|||||
Notional Amount |
Maturity Date |
Fair Value |
||||||||||
| Pay-fixed interest rate swaps |
$ |
$ |
( |
) | ||||||||
| Pay-fixed interest rate swaps |
( |
) | ||||||||||
| Derivatives in Cash Flow Hedging Relationships |
Amount of Loss Recognized in OCI on Derivatives, Net of |
Location of Loss Reclassified from Accumulated OCI into Operations |
Amount of Loss Reclassified from Accumulated OCI into Operations |
|||||||||
| Interest rate swaps |
$ |
Interest expense |
$ |
|||||||||
September 30, 2020 |
||||||||||||||||
Fair Value Measurements Using |
||||||||||||||||
Fair Value |
Quoted Prices in Active Markets for Identical Assets and Liabilities (Level 1) |
Significant Other Observable Inputs (Level 2) |
Significant Unobservable Inputs (Level 3) |
|||||||||||||
| Assets: |
||||||||||||||||
| Investments of insurance subsidiaries: |
||||||||||||||||
| Debt securities |
$ |
$ |
— |
$ |
$ |
— |
||||||||||
| Money market funds and other |
— |
— |
||||||||||||||
| |
|
|
|
|
|
|
|
|||||||||
| Investments of insurance subsidiaries |
— |
|||||||||||||||
| Less amounts classified as current assets |
( |
) |
( |
) |
( |
) |
— |
|||||||||
| |
|
|
|
|
|
|
|
|||||||||
$ |
$ |
$ |
$ |
— |
||||||||||||
| |
|
|
|
|
|
|
|
|||||||||
| Liabilities: |
||||||||||||||||
| Interest rate swaps (Income taxes and other liabilities) |
$ |
$ |
— |
$ |
$ |
— |
||||||||||
December 31, 2019 |
||||||||||||||||
Fair Value Measurements Using |
||||||||||||||||
Fair Value |
Quoted Prices in Active Markets for Identical Assets and Liabilities (Level 1) |
Significant Other Observable Inputs (Level 2) |
Significant Unobservable Inputs (Level 3) |
|||||||||||||
| Assets: |
||||||||||||||||
| Investments of insurance subsidiaries: |
||||||||||||||||
| Debt securities |
$ |
$ |
— |
$ |
$ |
— |
||||||||||
| Money market funds and other |
— |
— |
||||||||||||||
| |
|
|
|
|
|
|
|
|||||||||
| Investments of insurance subsidiaries |
— |
|||||||||||||||
| Less amounts classified as current assets |
( |
) |
( |
) |
( |
) |
— |
|||||||||
| |
|
|
|
|
|
|
|
|||||||||
$ |
$ |
$ |
$ |
— |
||||||||||||
| |
|
|
|
|
|
|
|
|||||||||
| Interest rate swaps (Other) |
$ |
$ |
— |
$ |
$ |
— |
||||||||||
| Liabilities: |
||||||||||||||||
| Interest rate swaps (Income taxes and other liabilities) |
$ |
$ |
— |
$ |
$ |
— |
||||||||||
September 30, 2020 |
December 31, 2019 |
|||||||
| Senior secured asset-based revolving credit facility |
$ |
$ |
||||||
| Senior secured revolving credit facility |
||||||||
| Senior secured 364-day term loan facility |
||||||||
| Senior secured term loan facilities (effective interest rate of |
||||||||
| Senior secured notes (effective interest rate of |
||||||||
| Other senior secured debt (effective interest rate of |
||||||||
| |
|
|
|
|||||
| Senior secured debt |
||||||||
| Senior unsecured notes (effective interest rate of |
||||||||
| Debt issuance costs and discounts |
( |
) |
( |
) | ||||
| |
|
|
|
|||||
| Total debt (average life of |
||||||||
| Less amounts due within one year |
||||||||
| |
|
|
|
|||||
$ |
$ |
|||||||
| |
|
|
|
|||||
Unrealized Gains on Available- for-Sale Securities |
Foreign Currency Translation Adjustments |
Defined Benefit Plans |
Change in Fair Value of Derivative Instruments |
Total |
||||||||||||||||
| Balances at December 31, 2019 |
$ |
$ |
( |
) |
$ |
( |
) |
$ |
( |
) |
$ |
( |
) | |||||||
| Unrealized gains on available-for-sale |
||||||||||||||||||||
| Foreign currency translation adjustments, net of $ |
( |
) |
( |
) | ||||||||||||||||
| Change in fair value of derivative instruments, net of $ |
( |
) |
( |
) | ||||||||||||||||
| Expense reclassified into operations from other comprehensive income, net of $ |
||||||||||||||||||||
| |
|
|
|
|
|
|
|
|
|
|||||||||||
| Balances at September 30, 2020 |
$ |
$ |
( |
) |
$ |
( |
) |
$ |
( |
) |
$ |
( |
) | |||||||
| |
|
|
|
|
|
|
|
|
|
|||||||||||
Quarter |
Nine Months |
|||||||||||||||
2020 |
2019 |
2020 |
2019 |
|||||||||||||
| Revenues: |
||||||||||||||||
| National Group |
$ |
$ |
$ |
$ |
||||||||||||
| American Group |
||||||||||||||||
| Corporate and other |
||||||||||||||||
| |
|
|
|
|
|
|
|
|||||||||
$ |
$ |
$ |
$ |
|||||||||||||
| |
|
|
|
|
|
|
|
|||||||||
| Equity in earnings of affiliates: |
||||||||||||||||
| National Group |
$ |
( |
) |
$ |
$ |
( |
) |
$ |
( |
) | ||||||
| American Group |
( |
) |
( |
) |
( |
) |
( |
) | ||||||||
| Corporate and other |
( |
) |
||||||||||||||
| |
|
|
|
|
|
|
|
|||||||||
$ |
( |
) |
$ |
( |
) |
$ |
( |
) |
$ |
( |
) | |||||
| |
|
|
|
|
|
|
|
|||||||||
| Adjusted segment EBITDA: |
||||||||||||||||
| National Group |
$ |
$ |
$ |
$ |
||||||||||||
| American Group |
||||||||||||||||
| Corporate and other |
( |
) |
( |
) |
( |
) |
( |
) | ||||||||
| |
|
|
|
|
|
|
|
|||||||||
$ |
$ |
$ |
$ |
|||||||||||||
| |
|
|
|
|
|
|
|
|||||||||
| Depreciation and amortization: |
||||||||||||||||
| National Group |
$ |
$ |
$ |
$ |
||||||||||||
| American Group |
||||||||||||||||
| Corporate and other |
||||||||||||||||
| |
|
|
|
|
|
|
|
|||||||||
$ |
$ |
$ |
$ |
|||||||||||||
| |
|
|
|
|
|
|
|
|||||||||
| Adjusted segment EBITDA |
$ |
$ |
$ |
$ |
||||||||||||
| Depreciation and amortization |
||||||||||||||||
| Interest expense |
||||||||||||||||
| Losses (gains) on sales of facilities |
( |
) |
( |
) | ||||||||||||
| Losses on retirement of debt |
||||||||||||||||
| |
|
|
|
|
|
|
|
|||||||||
| Income before income taxes |
$ |
$ |
$ |
$ |
||||||||||||
| |
|
|
|
|
|
|
|
|||||||||
Quarter |
||||||||||||||||
2020 |
Ratio |
2019 |
Ratio |
|||||||||||||
| Medicare |
$ |
2,603 |
19.6 |
% |
$ |
2,592 |
20.4 |
% | ||||||||
| Managed Medicare |
1,760 |
13.2 |
1,615 |
12.7 |
||||||||||||
| Medicaid |
445 |
3.3 |
361 |
2.8 |
||||||||||||
| Managed Medicaid |
707 |
5.3 |
641 |
5.0 |
||||||||||||
| Managed care and insurers |
6,752 |
50.7 |
6,554 |
51.7 |
||||||||||||
| International (managed care and insurers) |
307 |
2.3 |
282 |
2.2 |
||||||||||||
| Other |
737 |
5.6 |
649 |
5.2 |
||||||||||||
| |
|
|
|
|
|
|
|
|||||||||
| Revenues |
$ |
13,311 |
100.0 |
% |
$ |
12,694 |
100.0 |
% | ||||||||
| |
|
|
|
|
|
|
|
|||||||||
Nine Months |
||||||||||||||||
2020 |
Ratio |
2019 |
Ratio |
|||||||||||||
| Medicare |
$ |
7,618 |
20.5 |
% |
$ |
7,997 |
21.2 |
% | ||||||||
| Managed Medicare |
5,074 |
13.6 |
4,799 |
12.7 |
||||||||||||
| Medicaid |
1,423 |
3.8 |
1,124 |
3.0 |
||||||||||||
| Managed Medicaid |
1,904 |
5.1 |
1,808 |
4.8 |
||||||||||||
| Managed care and insurers |
19,028 |
51.0 |
19,405 |
51.1 |
||||||||||||
| International (managed care and insurers) |
838 |
2.3 |
863 |
2.3 |
||||||||||||
| Other |
1,355 |
3.7 |
1,817 |
4.9 |
||||||||||||
| |
|
|
|
|
|
|
|
|||||||||
| Revenues |
$ |
37,240 |
100.0 |
% |
$ |
37,813 |
100.0 |
% | ||||||||
| |
|
|
|
|
|
|
|
|||||||||
Quarter |
Nine Months |
|||||||||||||||
2020 |
2019 |
2020 |
2019 |
|||||||||||||
| Patient care costs (salaries and benefits, supplies, other operating expenses and depreciation and amortization) |
$ |
11,170 |
$ |
11,060 |
$ |
32,428 |
$ |
32,619 |
||||||||
| Cost-to-charges |
12.0 |
% |
12.3 |
% |
12.1 |
% |
12.1 |
% | ||||||||
| Total uncompensated care |
$ |
7,023 |
$ |
7,923 |
$ |
21,625 |
$ |
22,703 |
||||||||
| Multiply by the cost-to-charges |
12.0 |
% |
12.3 |
% |
12.1 |
% |
12.1 |
% | ||||||||
| |
|
|
|
|
|
|
|
|||||||||
| Estimated cost of total uncompensated care |
$ |
843 |
$ |
975 |
$ |
2,617 |
$ |
2,747 |
||||||||
| |
|
|
|
|
|
|
|
|||||||||
Quarter |
Nine Months |
|||||||||||||||
2020 |
2019 |
2020 |
2019 |
|||||||||||||
| Medicare |
25 |
% |
28 |
% |
26 |
% |
29 |
% | ||||||||
| Managed Medicare |
19 |
18 |
19 |
19 |
||||||||||||
| Medicaid |
5 |
5 |
6 |
5 |
||||||||||||
| Managed Medicaid |
13 |
12 |
12 |
12 |
||||||||||||
| Managed care and insurers |
30 |
28 |
29 |
27 |
||||||||||||
| Uninsured |
8 |
9 |
8 |
8 |
||||||||||||
| |
|
|
|
|
|
|
|
|||||||||
100 |
% |
100 |
% |
100 |
% |
100 |
% | |||||||||
| |
|
|
|
|
|
|
|
|||||||||
Quarter |
Nine Months |
|||||||||||||||
2020 |
2019 |
2020 |
2019 |
|||||||||||||
| Medicare |
25 |
% |
28 |
% |
27 |
% |
28 |
% | ||||||||
| Managed Medicare |
15 |
14 |
15 |
15 |
||||||||||||
| Medicaid |
5 |
4 |
5 |
4 |
||||||||||||
| Managed Medicaid |
6 |
6 |
6 |
5 |
||||||||||||
| Managed care and insurers |
49 |
47 |
47 |
47 |
||||||||||||
| Uninsured |
— |
1 |
— |
1 |
||||||||||||
| |
|
|
|
|
|
|
|
|||||||||
100 |
% |
100 |
% |
100 |
% |
100 |
% | |||||||||
| |
|
|
|
|
|
|
|
|||||||||
Quarter |
||||||||||||||||
2020 |
2019 |
|||||||||||||||
Amount |
Ratio |
Amount |
Ratio |
|||||||||||||
| Revenues |
$ |
13,311 |
100.0 |
$ |
12,694 |
100.0 |
||||||||||
| Salaries and benefits |
6,097 |
45.8 |
5,971 |
47.0 |
||||||||||||
| Supplies |
2,128 |
16.0 |
2,090 |
16.5 |
||||||||||||
| Other operating expenses |
2,251 |
16.9 |
2,352 |
18.5 |
||||||||||||
| Government stimulus income reversal |
822 |
6.2 |
— |
— |
||||||||||||
| Equity in earnings of affiliates |
(40 |
) |
(0.3 |
) |
(4 |
) |
— |
|||||||||
| Depreciation and amortization |
694 |
5.2 |
647 |
5.1 |
||||||||||||
| Interest expense |
385 |
2.9 |
448 |
3.5 |
||||||||||||
| Gains on sales of facilities |
(14 |
) |
( 0.1 |
) |
— |
— |
||||||||||
| Losses on retirement of debt |
— |
— |
211 |
1.7 |
||||||||||||
| |
|
|
|
|
|
|
|
|||||||||
12,323 |
92.6 |
11,715 |
92.3 |
|||||||||||||
| |
|
|
|
|
|
|
|
|||||||||
| Income before income taxes |
988 |
7.4 |
979 |
7.7 |
||||||||||||
| Provision for income taxes |
209 |
1.5 |
215 |
1.7 |
||||||||||||
| |
|
|
|
|
|
|
|
|||||||||
| Net income |
779 |
5.9 |
764 |
6.0 |
||||||||||||
| Net income attributable to noncontrolling interests |
111 |
0.9 |
152 |
1.2 |
||||||||||||
| |
|
|
|
|
|
|
|
|||||||||
| Net income attributable to HCA Healthcare, Inc. |
$ |
668 |
5.0 |
$ |
612 |
4.8 |
||||||||||
| |
|
|
|
|
|
|
|
|||||||||
| % changes from prior year: |
||||||||||||||||
| Revenues |
4.9 |
% |
10.9 |
% |
||||||||||||
| Income before income taxes |
0.9 |
(8.4 |
) |
|||||||||||||
| Net income attributable to HCA Healthcare, Inc. |
9.0 |
(19.3 |
) |
|||||||||||||
| Admissions(a) |
(3.9 |
) |
5.9 |
|||||||||||||
| Equivalent admissions(b) |
(9.1 |
) |
7.5 |
|||||||||||||
| Revenue per equivalent admission |
15.3 |
3.1 |
||||||||||||||
| Same facility % changes from prior year(c): |
||||||||||||||||
| Revenues |
4.5 |
6.3 |
||||||||||||||
| Admissions(a) |
(3.8 |
) |
3.2 |
|||||||||||||
| Equivalent admissions(b) |
(9.0 |
) |
4.2 |
|||||||||||||
| Revenue per equivalent admission |
14.8 |
2.0 |
||||||||||||||
Nine Months |
||||||||||||||||
2020 |
2019 |
|||||||||||||||
Amount |
Ratio |
Amount |
Ratio |
|||||||||||||
| Revenues |
$ |
37,240 |
100.0 |
$ |
37,813 |
100.0 |
||||||||||
| Salaries and benefits |
17,545 |
47.1 |
17,455 |
46.2 |
||||||||||||
| Supplies |
5,999 |
16.1 |
6,249 |
16.5 |
||||||||||||
| Other operating expenses |
6,825 |
18.3 |
7,013 |
18.6 |
||||||||||||
| Equity in earnings of affiliates |
(48 |
) |
(0.1 |
) |
(23 |
) |
(0.1 |
) | ||||||||
| Depreciation and amortization |
2,059 |
5.6 |
1,902 |
4.9 |
||||||||||||
| Interest expense |
1,201 |
3.2 |
1,386 |
3.7 |
||||||||||||
| Losses (gains) on sales of facilities |
6 |
— |
(17 |
) |
— |
|||||||||||
| Losses on retirement of debt |
295 |
0.8 |
211 |
0.6 |
||||||||||||
| |
|
|
|
|
|
|
|
|||||||||
33,882 |
91.0 |
34,176 |
90.4 |
|||||||||||||
| |
|
|
|
|
|
|
|
|||||||||
| Income before income taxes |
3,358 |
9.0 |
3,637 |
9.6 |
||||||||||||
| Provision for income taxes |
665 |
1.8 |
765 |
2.0 |
||||||||||||
| |
|
|
|
|
|
|
|
|||||||||
| Net income |
2,693 |
7.2 |
2,872 |
7.6 |
||||||||||||
| Net income attributable to noncontrolling interests |
365 |
0.9 |
438 |
1.2 |
||||||||||||
| |
|
|
|
|
|
|
|
|||||||||
| Net income attributable to HCA Healthcare, Inc. |
$ |
2,328 |
6.3 |
$ |
2,434 |
6.4 |
||||||||||
| |
|
|
|
|
|
|
|
|||||||||
| % changes from prior year: |
||||||||||||||||
| Revenues |
(1.5 |
)% |
9.9 |
% |
||||||||||||
| Income before income taxes |
(7.7 |
) |
(5.4 |
) |
||||||||||||
| Net income attributable to HCA Healthcare, Inc. |
(4.4 |
) |
(10.6 |
) |
||||||||||||
| Admissions(a) |
(5.1 |
) |
4.6 |
|||||||||||||
| Equivalent admissions(b) |
(9.8 |
) |
6.2 |
|||||||||||||
| Revenue per equivalent admission |
9.1 |
3.5 |
||||||||||||||
| Same facility % changes from prior year(c): |
||||||||||||||||
| Revenues |
(2.1 |
) |
5.7 |
|||||||||||||
| Admissions(a) |
(5.3 |
) |
2.1 |
|||||||||||||
| Equivalent admissions(b) |
(9.9 |
) |
3.0 |
|||||||||||||
| Revenue per equivalent admission |
8.6 |
2.6 |
||||||||||||||
(a) |
Represents the total number of patients admitted to our hospitals and is used by management and certain investors as a general measure of inpatient volume. |
(b) |
Equivalent admissions are used by management and certain investors as a general measure of combined inpatient and outpatient volume. Equivalent admissions are computed by multiplying admissions (inpatient volume) by the sum of gross inpatient revenues and gross outpatient revenues and then dividing the resulting amount by gross inpatient revenues. The equivalent admissions computation “equates” outpatient revenues to the volume measure (admissions) used to measure inpatient volume, resulting in a general measure of combined inpatient and outpatient volume. |
(c) |
Same facility information excludes the operations of hospitals and their related facilities which were either acquired or divested during the current and prior period. |
Nine Months September 30, 2020 |
Year December 31, 2019 |
|||||||
| Revenues |
$ |
22,406 |
$ |
29,220 |
||||
| Income before income taxes |
2,642 |
3,912 |
||||||
| Net income |
2,071 |
2,993 |
||||||
| Net income attributable to Parent, Subsidiary Issuer and Subsidiary Guarantors |
2,017 |
2,902 |
||||||
| At September 30, 2020 and December 31, 2019: |
||||||||
September 30, 2020 |
December 31, 2019 |
|||||||
| Current assets |
$ |
11,252 |
$ |
6,090 |
||||
| Property and equipment, net |
14,795 |
13,418 |
||||||
| Goodwill and other intangible assets |
5,777 |
5,743 |
||||||
| Total noncurrent assets |
21,640 |
19,977 |
||||||
| Total assets |
32,892 |
26,067 |
||||||
| Current liabilities |
9,528 |
4,504 |
||||||
| Long-term debt, net |
30,457 |
33,227 |
||||||
| Intercompany balances |
2,901 |
(53 |
) | |||||
| Income taxes and other liabilities |
799 |
879 |
||||||
| Total noncurrent liabilities |
34,654 |
34,398 |
||||||
| Stockholders’ deficit attributable to Parent, Subsidiary Issuer and Subsidiary Guarantors |
(11,392 |
) |
(12,941 |
) | ||||
| Noncontrolling interests |
102 |
106 |
||||||
2020 |
2019 |
|||||||
| Number of hospitals in operation at: |
||||||||
| March 31 |
186 |
185 |
||||||
| June 30 |
186 |
184 |
||||||
| September 30 |
187 |
184 |
||||||
| December 31 |
184 |
|||||||
| Number of freestanding outpatient surgical centers in operation at: |
||||||||
| March 31 |
123 |
124 |
||||||
| June 30 |
122 |
125 |
||||||
| September 30 |
121 |
125 |
||||||
| December 31 |
123 |
|||||||
| Licensed hospital beds at(a): |
||||||||
| March 31 |
49,357 |
48,455 |
||||||
| June 30 |
49,403 |
48,483 |
||||||
| September 30 |
49,473 |
48,588 |
||||||
| December 31 |
49,035 |
|||||||
| Weighted average licensed beds(b): |
||||||||
| Quarter: |
||||||||
| First |
49,160 |
48,036 |
||||||
| Second |
49,358 |
48,429 |
||||||
| Third |
49,479 |
48,535 |
||||||
| Fourth |
48,911 |
|||||||
| Year |
48,480 |
|||||||
| Average daily census(c): |
||||||||
| Quarter: |
||||||||
| First |
28,822 |
28,966 |
||||||
| Second |
24,844 |
27,808 |
||||||
| Third |
28,186 |
27,502 |
||||||
| Fourth |
28,274 |
|||||||
| Year |
28,134 |
|||||||
| Admissions(d): |
||||||||
| Quarter: |
||||||||
| First |
528,244 |
523,196 |
||||||
| Second |
452,992 |
518,253 |
||||||
| Third |
506,756 |
527,284 |
||||||
| Fourth |
540,194 |
|||||||
| Year |
2,108,927 |
|||||||
| Equivalent admissions(e): |
||||||||
| Quarter: |
||||||||
| First |
889,035 |
889,956 |
||||||
| Second |
723,136 |
903,419 |
||||||
| Third |
835,576 |
918,964 |
||||||
| Fourth |
933,996 |
|||||||
| Year |
3,646,335 |
|||||||
2020 |
2019 |
|||||||
| Average length of stay (days)(f): |
||||||||
| Quarter: |
||||||||
| First |
5.0 |
5.0 |
||||||
| Second |
5.0 |
4.9 |
||||||
| Third |
5.1 |
4.8 |
||||||
| Fourth |
4.8 |
|||||||
| Year |
4.9 |
|||||||
| Emergency room visits(g): |
||||||||
| Quarter: |
||||||||
| First |
2,264,707 |
2,287,440 |
||||||
| Second |
1,516,116 |
2,253,337 |
||||||
| Third |
1,813,661 |
2,269,364 |
||||||
| Fourth |
2,350,988 |
|||||||
| Year |
9,161,129 |
|||||||
| Outpatient surgeries(h): |
||||||||
| Quarter: |
||||||||
| First |
226,319 |
240,846 |
||||||
| Second |
170,911 |
253,441 |
||||||
| Third |
232,493 |
249,177 |
||||||
| Fourth |
266,483 |
|||||||
| Year |
1,009,947 |
|||||||
| Inpatient surgeries(i): |
||||||||
| Quarter: |
||||||||
| First |
135,145 |
137,363 |
||||||
| Second |
118,591 |
140,473 |
||||||
| Third |
133,492 |
143,215 |
||||||
| Fourth |
145,584 |
|||||||
| Year |
566,635 |
|||||||
| Days revenues in accounts receivable(j): |
||||||||
| Quarter: |
||||||||
| First |
49 |
53 |
||||||
| Second |
50 |
52 |
||||||
| Third |
44 |
52 |
||||||
| Fourth |
50 |
|||||||
| Outpatient revenues as a % of patient revenues(k): |
||||||||
| Quarter: |
||||||||
| First |
37 |
% |
38 |
% | ||||
| Second |
32 |
% |
39 |
% | ||||
| Third |
36 |
% |
39 |
% | ||||
| Fourth |
39 |
% | ||||||
| Year |
39 |
% | ||||||
(a) |
Licensed beds are those beds for which a facility has been granted approval to operate from the applicable state licensing agency. |
(b) |
Represents the average number of licensed beds, weighted based on periods owned. |
(c) |
Represents the average number of patients in our hospital beds each day. |
(d) |
Represents the total number of patients admitted to our hospitals and is used by management and certain investors as a general measure of inpatient volume. |
(e) |
Equivalent admissions are used by management and certain investors as a general measure of combined inpatient and outpatient volume. Equivalent admissions are computed by multiplying admissions (inpatient volume) by the sum of gross inpatient revenues and gross outpatient revenues and then dividing the resulting amount by gross inpatient revenues. The equivalent admissions computation “equates” outpatient revenues to the volume measure (admissions) used to measure inpatient volume resulting in a general measure of combined inpatient and outpatient volume. |
(f) |
Represents the average number of days admitted patients stay in our hospitals. |
(g) |
Represents the number of patients treated in our emergency rooms. |
(h) |
Represents the number of surgeries performed on patients who were not admitted to our hospitals. Pain management and endoscopy procedures are not included in outpatient surgeries. |
(i) |
Represents the number of surgeries performed on patients who have been admitted to our hospitals. Pain management and endoscopy procedures are not included in inpatient surgeries. |
(j) |
Revenues per day is calculated by dividing revenues for the quarter by the days in the quarter. Days revenues in accounts receivable is then calculated as accounts receivable at the end of the quarter divided by revenues per day. |
(k) |
Represents the percentage of patient revenues related to patients who are not admitted to our hospitals. |
ITEM 2. UNREGISTERED |
SALES OF EQUITY SECURITIES AND USE OF PROCEEDS |
ITEM 6. EXHIBITS |
22 |
— |
|||
31.1 |
— |
|||
31.2 |
— |
|||
32 |
— |
|||
101 |
— |
The following financial information from our quarterly report on Form 10-Q for the quarters and nine months ended September 30, 2020 and 2019, filed with the SEC on October 29, 2020, formatted in Inline Extensible Business Reporting Language: (i) the condensed consolidated balance sheets at September 30, 2020 and December 31, 2019, (ii) the condensed consolidated income statements for the quarters and nine months ended September 30, 2020 and 2019, (iii) the condensed consolidated comprehensive income statements for the quarters and nine months ended September 30, 2020 and 2019, (iv) the condensed consolidated statements of stockholders’ equity (deficit) for the quarters and nine months ended September 30, 2020 and 2019, (v) the condensed consolidated statements of cash flows for the nine months ended September 30, 2020 and 2019 and (vi) the notes to condensed consolidated financial statements. The instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. | ||
104 |
— |
The cover page from the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2020, formatted in Inline XBRL (included in Exhibit 101). | ||
| HCA Healthcare, Inc. | ||
| By: |
/S/ WILLIAM B. RUTHERFORD | |
William B. Rutherford | ||
Executive Vice President and Chief Financial Officer | ||
EXHIBIT 31.1
CERTIFICATION
I, Samuel N. Hazen, certify that:
1. I have reviewed this quarterly report on Form 10-Q of HCA Healthcare, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
| By: |
/S/ SAMUEL N. HAZEN | |
| Samuel N. Hazen | ||
| Chief Executive Officer |
Date: October 29, 2020
EXHIBIT 31.2
CERTIFICATION
I, William B. Rutherford, certify that:
1. I have reviewed this quarterly report on Form 10-Q of HCA Healthcare, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
| By: |
/S/ WILLIAM B. RUTHERFORD | |
| William B. Rutherford | ||
| Executive Vice President and Chief Financial Officer |
Date: October 29, 2020
EXHIBIT 32
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of HCA Healthcare, Inc. (the “Company”) on Form 10-Q for the quarter ended September 30, 2020, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
| By: |
/S/ SAMUEL N. HAZEN | |
| Samuel N. Hazen | ||
| Chief Executive Officer |
October 29, 2020
| By: |
/S/ WILLIAM B. RUTHERFORD | |
|
William B. Rutherford | ||
| Executive Vice President and Chief Financial Officer |
October 29, 2020